CMS Selects Qlarant as the Investigations Medicare Drug Integrity Contractor to Detect, Prevent, and Deter Fraud, Waste, and Abuse
Easton, Maryland—The Centers for Medicare & Medicaid Services (CMS) has selected Qlarant as the Investigations Medicare Drug Integrity Contractor (I-MEDIC) to detect, prevent, and proactively deter fraud, waste, and abuse (FWA) in Medicare Programs. This designation will allow Qlarant to perform these functions in the plans commonly known as Parts C & D.
“We are extremely excited to have this opportunity,” said Carrie Ward, Senior Vice President of Qlarant. “We have a dedicated team of professionals comprised of investigators, pharmacists, nurses, and data analysts who bring extensive experience and subject matter expertise to the work at hand. We are ready and prepared to do this important work.”
Under CMS direction, Qlarant will perform various functions related to potential fraud, waste and abuse from prescribers, pharmacies, and beneficiaries. The primary focus will be on complaint intake and response, data analysis, assessing leads, investigative action, administrative actions and program integrity. The program is required to work in compliance with all federal and state laws, regulations, and CMS requirements.
Qlarant, headquartered in Easton, Maryland, is a national leader in battling FWA and has offices and home-based associates across the country. “We look forward to the opportunity to continue working to ensure Medicare and Medicaid funds are properly protected,” commented Sandy Love, President, Qlarant Integrity Solutions.
CMS’ goals are to achieve enhanced FWA detection and prevention, ultimately saving millions of dollars annually. Qlarant uses a combination of advanced technology, data analytics, and expert evaluation to provide a powerful process consistent with CMS’s goals and expectations, which will ultimately benefit Medicare beneficiaries and recipients.